Glenmark Pharmaceuticals to Launch Zanubrutinib for Cancer Treatment in India
June 19, 2025 | Mumbai: Glenmark Pharmaceuticals, a leading Indian multinational pharmaceutical company, announced on Monday its plans to launch zanubrutinib, a breakthrough cancer therapy, in the Indian market.
This move aims to make cutting-edge cancer therapies more accessible and affordable in India, addressing a growing need for targeted oncology treatments.
The move marks a significant step forward in expanding access to advanced oncology treatments for patients across the country.
Zanubrutinib is a next-generation Bruton’s tyrosine kinase (BTK) inhibitor used in the treatment of certain hematological malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia (CLL), and Waldenström’s macroglobulinemia.
It is designed to offer improved selectivity and sustained BTK inhibition, which translates into better efficacy and safety outcomes compared to earlier-generation BTK inhibitors.
With this launch, Glenmark aims to bridge the gap between cutting-edge global cancer therapies and their accessibility in India.
The company is expected to offer zanubrutinib at a significantly reduced price compared to international markets, potentially bringing relief to thousands of cancer patients in need of affordable treatment options.
“We are proud to introduce zanubrutinib in India, reinforcing our commitment to advancing cancer care and improving quality of life for patients,” said a Glenmark spokesperson. “This addition to our oncology portfolio represents not just innovation, but also accessibility.”
Zanubrutinib was developed by BeiGene, a global biotechnology company.
Glenmark’s launch follows its agreement to commercialize the drug in India, where the burden of blood cancers is steadily increasing.
The availability of such targeted therapies is crucial for effective disease management and long-term remission.
As Glenmark prepares for the rollout, oncologists and healthcare professionals across India are optimistic that this new therapy will set a benchmark for future cancer treatments in the country.
References
Business Standard reported Glenmark’s plan to introduce zanubrutinib (BRUKINSA) following DCGI approval https://www.business-standard.com/companies/news/glenmark-launches-brukinsa-blood-cancer-drug-india-dcgi-approval-125060900909_1.html